tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol
. 2021 Mar 30.
doi: 10.1111/jdv.17248. Online ahead of print.
Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine
M Ackerman[SUP] 1 [/SUP], D Henry[SUP] 1 [/SUP], A Finon[SUP] 1 [/SUP], R Binois[SUP] 1 [/SUP], E Esteve[SUP] 1 [/SUP]
Affiliations
Abstract
The ongoing global pandemic COVID-19 led regulatory agencies to recently issue an emergency authorization for two effective Covid-19 vaccines from Pfizer-BioNTech and Moderna. Both vaccines use a novel technology of administering vaccination, namely a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the spike glycoprotein of SARS-CoV-2 for subsequent antigen presentation and immune system activation (1).
Keywords: COVID-19; adverse event; coronavirus; cutaneous; mRNA vaccine; maculopapular rash.
. 2021 Mar 30.
doi: 10.1111/jdv.17248. Online ahead of print.
Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine
M Ackerman[SUP] 1 [/SUP], D Henry[SUP] 1 [/SUP], A Finon[SUP] 1 [/SUP], R Binois[SUP] 1 [/SUP], E Esteve[SUP] 1 [/SUP]
Affiliations
- PMID: 33783017
- DOI: 10.1111/jdv.17248
Abstract
The ongoing global pandemic COVID-19 led regulatory agencies to recently issue an emergency authorization for two effective Covid-19 vaccines from Pfizer-BioNTech and Moderna. Both vaccines use a novel technology of administering vaccination, namely a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the spike glycoprotein of SARS-CoV-2 for subsequent antigen presentation and immune system activation (1).
Keywords: COVID-19; adverse event; coronavirus; cutaneous; mRNA vaccine; maculopapular rash.